Details for Patent: 9,249,416
✉ Email this page to a colleague
| Title: | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| Abstract: | An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. |
| Inventor(s): | Wilton; Stephen Donald (Applecross, AU), Fletcher; Sue (Bayswater, AU), McClorey; Graham (Bayswater, AU) |
| Assignee: | The University of Western Australia (Crawley, AU) |
| Filing Date: | Sep 11, 2015 |
| Application Number: | 14/852,149 |
| Claims: | 1.155(b)(2) and SO 155.1.3 and 155.1.4), dated Mar. 9, 2015, (University of Western Australia Exhibit 2138, filed Apr. 3, 2015 in Interferences 106007, 106008, and 106013, pp. 1-4). cited by applicant . Fragall, Clayton T. et al., "Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching," BMC Medical Genetics, vol. 12:141, 8 pages (2011) (Exhibit No. 2019 filed in interferences 106008, 106013, 106007 on Nov. 18, 2014). cited by applicant . Fraley, Robert et al., "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids," Trends Biochem., vol. 6:77-80 (1981). cited by applicant . Frazier, Kendall S. et al., "Species-specific Inflammatory Responses as a Primary Component for the Development of Glomerular Lesions in Mice and Monkeys Following Chronic Administration of a Second-generation Antisense Oligonucleotide," Toxicologica Pathology, 13 pages (2013). cited by applicant . Friedmann, Theodore, "Progress Toward Human Gene Therapy," Science, vol. 244(4910):1275-1281 (1989). cited by applicant . Gebski, Bianca L. et al., "Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle," Human Molecular Genetics, vol. 12(15):1801-1811 (2003). cited by applicant . Generic Method for Average Mass Determination Using LC-UV-MS in the Negative Mode, pp. 15, Exhibit No. 1145 filed in Interferences 106,007 and 106,008 on Feb. 16, 2015. cited by applicant . Generic UPLC Purity Method for Oligonucleotides (19- to 25-mers), pp. 18, Exhibit No. 1156 filed in Interferences 106,007 and 106,008 on Feb. 16, 2015. cited by applicant . Gennaro, Alfonso R., (ed.), Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing, Co., Easton PA, 2020 pages (1990). cited by applicant . Giles, Richard V. et al., "Antisense Morpholino Oligonucleotide Analog Induces Missplicing of C-myc mRNA," Antisense & Nucleic Acid Drug Development, vol. 9:213-220 (1999). cited by applicant . GlaxoSmithKline Press Release, Issued in London, UK, dated Jun. 27, 2013 (5 pages), Exhibit No. 1202 filed in Interferences 106,007 and 106,008 on Feb. 17, 2015. cited by applicant . GlaxoSmithKline, "GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication," press release, 6 pages, dated Jan. 19, 2011 (Exhibit No. 2060 filed in interferences 106008, 106013, 106007 on Nov. 18, 2014). cited by applicant . GlaxoSmithKline, Prosensa regains rights to drisapersen from GSK and retains rights to all other programmes for the treatment of Duchenne muscular dystrophy (DMD), press release, 4 pages, dated Jan. 13, 2014 (Exhibit 2040 in Interferences 106007, 106008, and 106013 on Nov. 18, 2014). cited by applicant . Goemans, Nathalie M. et al., "Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy," The New England Journal of Medicine, vol. 364:1513-1522 (2011) (Exhibit No. 2036 filed in interferences 106008, 106013, 106007 on Nov. 18, 2014). cited by applicant . Gordon, Peter M. et al., "Metal ion catalysis during the exon-ligation step of nuclear pre-mRNA splicing: Extending the parallels between the spliceosome and group II introns," RNA, vol. 6:199-205 (2000) (Exhibit No. 1055 filed in interferences 106008, 106007 on Nov. 18, 2014). cited by applicant . Gordon, Peter M., et al., "Kinetic Characterization of the Second Step of Group II Intron Splicing: Role of Metal Ions and the Cleavage Site 2'-OH in Catalysis," Biochemistry, vol. 39, pp. 12939-12952 (2000), Exhibit No. 1188 filed in Interferences 106,007 and 106,008 on Feb. 17, 2015. cited by applicant . Goyenvalle, Aurelie et al., "Prevention of Dystrophic Pathology in Severely Affected Dystrophin/Utrophin-deficient Mice by Morpholino-oligomer-mediated Exon-skipping," Molecular Therapy, vol. 18(1):198-205 (2010). cited by applicant . Hammond, Suzan M. et al., "Correlating in Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides," Molecular Therapy--Nucleic Acids, vol. 3:1, 11 pages (2014) (Exhibit No. 2011 filed in interferences 106008, 106013, 106007 on Nov. 18, 2014). cited by applicant . Hammond, Suzan M., et al., "Genetic therapies for RNA mis-splicing diseases," Cell, vol. 27, No. 5, pp. 196-205 (May, 2011), Exhibit No. 1113 filed in interferences 106,007 and 106,008 on Feb. 17, 2015. cited by applicant . Hammond,Suzan M., et al., "PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy," Curr. Opinion Mol. Therap., vol. 12, No. 4, pp. 478-486 (2010), Exhibit No. 1121 filed in interferences 106,007 and 106,008 on Feb. 13, 2015. cited by applicant . Harding, PL et al., "The Influence of Antisense Oligonucleotide Length on Dystrophin Exon Skipping," Molecular Therapy, vol. 15(1):157-166 (2007) (Exhibit No. 1030 filed in interferences 106008, 106007 on Nov. 18, 2014). cited by applicant . Harel-Bellan, Annick et al., "Specific Inhibition of c-myc Protein Biosynthesis Using an Antisense Synthetic Deoxy-Oligonucleotide in Human T Lymphocytes," The Journal of Immunology, vol. 140(7):2431-2435 (1988). cited by applicant . Havenga, M.J.E., et al., "Exploiting the Natural Diversity in Adenovirus Tropism for Therapy and Prevention of Disease," J. Virol., vol. 76, No. 9, pp. 4612-4620 (May, 2002), Exhibit No. 1123 filed in interferences 106,007 and 106,008 on Feb. 13, 2015. cited by applicant . Heasman, Janet, "Morpholino Oligos: Making Sense of Antisense?" Developmental Biology, vol. 243:209-214 (2002). cited by applicant . Heemskerk, Hans A. et al., "In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping," The Journal of Gene Medicine, vol. 11:257-266 (2009) (Exhibit No. 2020 filed in interferences 106008, 106013, 106007 on Nov. 18, 2014). cited by applicant . Heid, Christian A. et al., "Real Time Quantitative PCR," Genome Research, vol. 6:986-994 (1996) (Exhibit No. 1061 filed in interferences 106008, 106007 on Nov. 18, 2014). cited by applicant . Herschlag, Daniel et al., "Contributions of 2' Hydroxyl Groups of the RNA Substrate to Binding and Catalysis by the Tetrahymena Ribozyme: An Energetic Picture of an Active Site Composed of RNA," Biochemistry, vol. 32:8299-8311 (1993) (Exhibit No. 1031 filed in interferences 106008, 106007 on Nov. 18, 2014). cited by applicant . Hudziak, Robert M. et al., "Antiproliferative Effects of Steric Blocking Phosphorodiamidate Morpholino Antisense Agents Directed against c-myc," Antisense & Nucleic Acid Drug Development, vol. 10:163-176 (2000) (Exhibit No. 1032 filed in interferences 106008, 106007 on Nov. 18, 2014). cited by applicant . Hudziak, Robert M. et al., "Resistance of Morpholino Phosphorodiamidate Oligomers to Enzymatic Degradation," Antisense & Nucleic Acid Drug Development, vol. 6:267-272 (1996). cited by applicant . Hussey, Nicole D. et al., "Analysis of five Duchenne muscular dystrophy exons and gender determination using conventional duplex polymerase chain reaction on single cells," Molecular Human Reproduction, vol. 5(11):1089-1094 (1999). cited by applicant . Interim Guidance on Patent Subject Matter Eligibility ("the December Guidance," 16 pages,(Exhibit No. 2119 filed in interferences 106,007 and 106,008 on Feb. 17, 2015. cited by applicant . International Patent Application No. PCT/AU2000/00693 ("Wraight"), published as WO 00/78341 on Dec. 28, 2000, 201 pages, (Exhibit No. 2125 filed in interferences 106,007 and 106,008 on Feb. 17, 2015. cited by applicant . International Preliminary Report on Patentability and Written Opinion for Application No. PCT/US2009/061960, 8 pages, dated Apr. 26, 2011. cited by applicant . International Preliminary Report on Patentability for Application No. PCT/AU2005/000943, 8 pages, dated Dec. 28, 2006. cited by applicant . International Preliminary Report on Patentability, PCT/US2013/077216, dated Jun. 23, 2015, pp. 1-7. cited by applicant . International Preliminary Report on Patentability, PCT/US2014/029610, dated Jul. 1, 2015, pp. 1-122. cited by applicant . International Search Report and Written Opinion of the International Searching Authority issued in International Patent Application No. PCT/US2013/077216, 5 pages, dated Mar. 27, 2014. cited by applicant . International Search Report and Written Opinion of the International Searching Authority issued in International Patent Application No. PCT/US2014/029610, 6 pages, dated Sep. 18, 2014. cited by applicant . International Search Report and Written Opinion of the International Searching Authority issued in International Patent Application No. PCT/US2014/029689, 8 pages, dated Oct. 21, 2014. cited by applicant . International Search Report and Written Opinion of the International Searching Authority issued in International Patent Application No. PCT/US2014/029766, 8 pages, dated Oct. 21, 2014. cited by applicant . International Search Report for Application No. PCT/AU2005/000943, 5 pages, dated Oct. 20, 2005. cited by applicant . International Search Report for Application No. PCT/US01/14410, 5 pages, dated Mar. 6, 2002. cited by applicant . "Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients," Clinical Trial Identifier No. NCT01396239, ClinicalTrials.gov, dated Jul. 15, 2011, p. 1-4. cited by applicant . Aartsma-Rus A, et al. "Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations," Hum Mutat 2009;30:293-99. cited by applicant . Ahmad A, et al., "Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy," Hum Mol Genet 2000;9:2507-2515. cited by applicant . Arechavala-Gomeza V, et al., "Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression," Neuropathol Appl Neurobiol 2010;36: 265-74. cited by applicant . AZL's PCT/NL03/00214 (the as-filed AZL PCT Application) Exhibit No. 1006, filed in Interference No. 106,007, 64 pages, Dec. 23, 2014. cited by applicant . Azofeifa J, et al., "X-chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes," Hum Genet 1995;96:167-176. cited by applicant . Brooke MH, et al., "Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history," Muscle Nerve. 1983;6:91-103. cited by applicant . Bushby K, et al. "Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management," Lancet Neurol 2010;9:77-93. cited by applicant . Bushby KM, et al., "The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy," II. Correlation of phenotype with genetic and protein abnormalities. J Neurol 1993;240: 105-112. cited by applicant . Bushby KM, et al., "The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy," I. Natural history. J Neurol 1993;240:98-104. cited by applicant . Confirmatory Study of Eteplirsen in DMD Patients, An Open-Label, Multi-Center, 48-Week Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy ,ClinicalTrials.gov, Clinical Trial Identifier NCT02255552, Oct. 1, 2014, 3 pages. cited by applicant . Confirmatory Study of Eteplirsen in DMD Patients, An Open-Label, Multi-Center, 48-Week Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy, ClinicalTrials.gov, Clinical Trial Identifier NCT02255552, May 26, 2015, 3 pages. cited by applicant . Emery, A.E. H., "Population frequencies of inherited neuromuscular diseases--a world survey," Neuromuscul Disord 1991;1:19-29. cited by applicant . File Excerpts from Prosecution History of U.S. Appl. No. 13/270,992 (UWA's U.S. Pat. No. 8,486,907), pp. 122, Exhibit No. 1006 filed in Interference 106,013 on Feb. 17, 2015. cited by applicant . Fletcher S., et al, Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 2007;15:1587-1592. cited by applicant . Hoffman EP, et al., "Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy" N Engl J Med 1988;318:1363-68. cited by applicant . Hoffman EP, et al., "Restoring dystrophin expression in Duchenne muscular dystrophy muscle: Progress in exon skipping and stop codon read through," Am J Path 2011;179:12-22. cited by applicant . Kohler M, et al., "Quality of life, physical disability and respiratory impairment in Duchenne muscular dystrophy," Am J Respir Crit Care Med 2005;172:1032-6. cited by applicant . Manzur A, et al.,. "Glucocorticoid corticosteroids for Duchenne muscular dystrophy," Cochrane Database Syst Rev. 2004;(2):CD003725. cited by applicant . Mazzone E, et al. "Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study," Neurology 2011;77(3):250-6. cited by applicant . McDonald CM, et al., "Profiles of Neuromuscular Diseases, Duchenne muscular dystrophy," Am J Phys Med Rehabil 1995;74:S70-S92. cited by applicant . McDonald CM, et al., "The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy," Muscle Nerve 2010;41:500-10. cited by applicant . McDonald CM, et al., "The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations," Muscle Nerve 2010;42: 966-74. cited by applicant . Mendell JR et al., "Evidence-based path to newborn screening for Duchenne muscular Dystrophy," Ann Neurol 2012;71:304-13. cited by applicant . Mendell JR, et al., "Dystrophin immunity revealed by gene therapy in Duchenne muscular dystrophy," N Engl J Med 2010;363:1429-37. cited by applicant . Mendell JR, et al., "Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy," N Engl J Med 1989;320:1592-97. cited by applicant . Merlini L, et al., "Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up," Muscle Nerve 2012;45:796-802. cited by applicant . Muntoni F, et al., "Dystrophin and mutations: one gene, several proteins, multiple phenotypes," Lancet Neurol. 2003;2:731-40. cited by applicant . Nguyen TM, et. Al, "Use of Epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy," Am J Hum Genet 1993;52:1057-66. cited by applicant . Statement on a Nonproprietary Name Adopted by the USAN Council, ETEPLIRSEN, Chemical Structure, 2010, pp. 1-5. cited by applicant . Strober JB, "Therapeutics in Duchenne muscular dystrophy," NeuroRX 2006; 3:225-34. cited by applicant . University of Western Australia v. Academisch Ziekenhuis Leiden, Statement Concerning Subsequent Settlement Discussions, iscussions, filed in Patent Interference No. 106,013, Aug. 24, 2015, pp. 1-3 (Doc 195). cited by applicant . University of Western Australia v. Academisch Ziekenhuis Leiden, UWA Notice of Recent Authority, filed in Patent Interference No. 106,007, Sep. 2, 2015, pp. 1-18 (Doc 470). cited by applicant . University of Western Australia v. Academisch Ziekenhuis Leiden, UWA Notice of Recent Authority, filed in Patent Interference No. 106,008, Sep. 2, 2015, pp. 1-18 (Doc 478). cited by applicant . van Putten M, et al., The Effects of Low Levels of Dystrophin on Mouse Muscle Function and Pathology. PLoS ONE 2012;7:e31937, 13 pages. cited by applicant . U.S. Appl. No. 14/213,641, Richard K. Bestwick, filed Mar. 14, 2014, mailed Oct. 16, 2015, D. Shin. cited by applicant . WO 2013/112053 A1, (University of Western Australia Exhibit 2130, filed Apr. 3, 2015 in Interferences 106007, 106008, and 106013, pp. 1-177). cited by applicant . Wolff, Jon A. et al., "Direct Gene Transfer into Mouse Muscle in Vivo," Science, vol. 247:1465-1468 (1990). cited by applicant . Wong, Marisa L. et al., "Real-time PCR for mRNA quantitation," BioTechniques, vol. 39:75-85 (2005) (Exhibit No. 1066 filed in interferences 106008, 106007 on Nov. 18, 2014). cited by applicant . Wood, "Toward an Oligonucleotide Therapy for Duchenne Muscular Dystrophy: A Complex Development Challenge," Science Translational Medicine, vol. 2, No. 25, pp. 1-6 (Mar. 2010), Exhibit No. 1116 filed in interferences 106,007 and 106,008 on Feb. 17, 2015,Doc 335. cited by applicant . Written Opinion for Application No. PCT/AU2010/001520, 6 pages, dated Jan. 21, 2011. cited by applicant . Wu, B. et al., "Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino," Gene Therapy, vol. 17:132-140 (2010). cited by applicant . Wu, Bo et al., "Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer," PNAS, vol. 105(39):14814-14819 (2008). cited by applicant . Wu, Bo et al., "Targeted Skipping of Human Dystrophin Exons in Transgenic Mouse Model Systemically for Antisense Drug Development," PLoS One, vol. 6(5):e19906, 11 pages (2011). cited by applicant . Wu, George Y. et al., "Receptor-mediated Gene Delivery and Expression in Vivo," The Journal of Biological Chemistry, vol. 263(29):14621-14624 (1988). cited by applicant . Wu, George Y. et al., "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," The Journal of Biological Chemistry, vol. 262(10):4429-4432 (1987). cited by applicant . Wyatt et al. "Site-specific cross-linking of mammalian U5 snRNP to the 5' splice site before the first step of pre-mRNA splicing," Genes & Development, vol. 6, pp. 2542-2553 (1992), Exhibit No. 1198 filed in Interferences 106,007 and 106,008 on Feb. 17, 2015. cited by applicant . Yin et al., "A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice," Human Mol. Gen., vol. 18, No. 22, pp. 4405-4414 (2009), Exhibit No. 1200 filed in Interferences 106,007 and 106,008 on Feb. 17, 2015. cited by applicant . Yin et al., "Cell Penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function," Human Mol. Gen., vol. 17, No. 24, pp. 3909-3918 (2008), Exhibit No. 1199 filed in Interferences 106,007 and 106,008 on Feb. 17, 2015. cited by applicant . Yin et al., "Functional Rescue of Dystrophin-deficient mdx Mice by a ChimericPeptide-PMO," Mol. Therapy, vol. 18, No. 10, pp. 1822-1829 (Oct. 2010), Exhibit No. 1117 filed in interferences 106,007 and 106,008 on Feb. 17, 2015. cited by applicant . Yokota et al., "Efficacy of Systematic Morpholino Exon-Skipping in Duchenne Dystrophy Dogs," American Neurological Assoc., vol. 65, No. 6, pp. 667-676 (Jun. 2009), Exhibit No. 1214 filed in Interferences 106,007 and 106,008 on Feb. 17, 2015. cited by applicant . Zoltek Corp. v. U.S., 95 Fed. Cl. 681 (2011), 23 pages, (Academisch Ziekenhuis Leiden Exhibit 1236, filed May 5, 2015 in Interference 106007 and 106008). cited by applicant . U.S. Appl. No. 11/570,691, filed Jan. 15, 2008 Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 12/837,356, filed Jul. 15, 2010, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 12/837,359, filed Jul. 15, 2010, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 12/860,078, filed Aug. 20, 2010, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/168,857, filed Jun. 24, 2011, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/168,863, filed Jun. 24, 2011, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/270,500, filed Oct. 11, 2011, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/270,531, filed Oct. 11, 2011, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/270,744, filed Oct. 11, 2011, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/270,937, filed Oct. 11, 2011, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/270,992, filed Oct. 11, 2011, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/271,080, filed Oct. 11, 2011, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/727,415, filed Dec. 26, 2012, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/741,150, filed Jan. 14, 2013, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/826,613, filed Mar. 14, 2013, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/826,880, filed Mar. 14, 2013, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/902,376, filed May 24, 2013, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 13/963,578, filed Aug. 9, 2013, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 14/086,859, filed Nov. 21, 2013, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 14/178,059, filed Feb. 11, 2014, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 14/223,634, filed Mar. 24, 2014, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 14/273,318, filed May 8, 2014, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 14/273,379, filed May 8, 2014, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 14/316,603, filed Jun. 26, 2014, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 14/316,609, filed Jun. 26, 2014, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 14/317,952, filed Jun. 27, 2014, Stephen Donald Wilton. cited by applicant . U.S. Appl. No. 12/605,276, filed Oct. 23, 2009, Peter Sazani. cited by applicant . U.S. Appl. No. 13/829,545, filed Mar. 14, 2013, Peter Sazani. cited by applicant . U.S. Appl. No. 13/830,253, filed Mar. 14, 2013, Peter Sazani. cited by applicant . U.S. Appl. No. 14/523,610, filed Oct. 24, 2014, Peter Sazani. cited by applicant . U.S. Appl. No. 14/213,629, Mar. 14, 2014, E.M. Kaye. cited by applicant . U.S. Appl. No. 14/214,567, Mar. 14, 2014, E.M. Kaye. cited by applicant . U.S. Appl. No. 14/213,607, Mar. 14, 2014, R.K. Bestwick. cited by applicant . U.S. Appl. No. 14/214,480, Mar. 14, 2014, R.K. Bestwick. cited by applicant . U.S. Appl. No. 13/509,331, Jul. 9, 2012, S.D. Wilton. cited by applicant . U.S. Appl. No. 14/108,137, Dec. 16, 2013, S.D. Wilton. cited by applicant . U.S. Appl. No. 14/213,641, Mar. 14, 2014, R.K. Bestwick. cited by applicant . U.S. Appl. No. 11/570,691, Aug. 16, 2010, Kimberly Chong. cited by applicant . U.S. Appl. No. 11/570,691, Mar. 15, 2010, Kimberly Chong. cited by applicant . U.S. Appl. No. 11/570,691, May 26, 2009, Kimberly Chong. cited by applicant . U.S. Appl. No. 12/837,356, May 3, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 12/837,356, Apr. 3, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 12/837,356, Aug. 2, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 12/837,359, Mar. 12, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 12/837,359, Oct. 5, 2011, Kimberly Chong. cited by applicant . U.S. Appl. No. 12/837,359, Mar. 30, 2011, Kimberly Chong. cited by applicant . U.S. Appl. No. 12/837,359, Dec. 22, 2010, Kimberly Chong. cited by applicant . U.S. Appl. No. 12/860,078, Feb. 14, 2011, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/168,857, Jul. 12, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/168,863, Mar. 8, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/168,863, Oct. 11, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/168,863, Aug. 8, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,500, Mar. 15, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,500, Jul. 30, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,500, Mar. 14, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,531, Jun. 28, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,531, Mar. 14, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,744, Apr. 3, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,744, Aug. 6, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,744, Mar. 14, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,937, Feb. 25, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,937, Jun. 14, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,937, Mar. 14, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,992, Apr. 4, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,992, Jul. 30, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/270,992, Mar. 16, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/271,080, Mar. 26, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/271,080, Jul. 30, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/271,080, Mar. 14, 2012, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/727,415, Feb. 6, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/741,150, Mar. 16, 2015, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/741,150, Sep. 18, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/741,150, Apr. 11, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/741,150, Sep. 24, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/826,613, Jul. 22, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/826,613, Jan. 7, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/826,613, Jul. 17, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/826,880, Jun. 22, 2015, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/826,880, Jan. 26, 2015, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/826,880, Apr. 15, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/826,880, Sep. 11, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/902,376, Jun. 5, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/902,376, Jan. 7, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/902,376, Jul. 18, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 13/963,578, Sep. 24, 2013, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/086,859, Jun. 30, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/086,859, Jan. 27, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/178,059, Mar. 31, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/223,634, Apr. 15, 2015, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/273,318, Oct. 20, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/273,318, Jul. 3, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/273,379, Jul. 7, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/316,603, Mar. 10, 2015, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/316,603, Sep. 26, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/316,609, Mar. 16, 2015, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/316,609, Oct. 21, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/317,952, Mar. 18, 2015, Kimberly Chong. cited by applicant . U.S. Appl. No. 14/317,952, Nov. 7, 2014, Kimberly Chong. cited by applicant . U.S. Appl. No. 12/605,276, Jun. 18, 2014, J. McDonald. cited by applicant . U.S. Appl. No. 12/605,276, Oct. 18, 2013, J. McDonald. cited by applicant . U.S. Appl. No. 12/605,276, Dec. 23, 2011, J. McDonald. cited by applicant . U.S. Appl. No. 12/605,276, Aug. 24, 2011, J. McDonald. cited by applicant . U.S. Appl. No. 12/605,276, Feb. 11, 2011, J. McDonald. cited by applicant . U.S. Appl. No. 13/829,545, Jun. 6, 2014, J. McDonald. cited by applicant . U.S. Appl. No. 13/830,253, Jun. 11, 2014, J. McDonald. cited by applicant . U.S. Appl. No. 13/830,253, Nov. 26, 2013, J. McDonald. cited by applicant . U.S. Appl. No. 14/214,567, Jun. 24, 2015, E. Poliakova-Georgan. cited by applicant . U.S. Appl. No. 14/213,607, Sep. 15, 2015, D.H. Shin. cited by applicant . U.S. Appl. No. 14/213,607, Apr. 1, 2015, D.H. Shin. cited by applicant . U.S. Appl. No. 14/213,607, Sep. 18, 2014, D.H. Shin. cited by applicant . U.S. Appl. No. 14/214,480, Apr. 17, 2015, D.H. Shin. cited by applicant . U.S. Appl. No. 14/214,480, Sep. 19, 2014, D.H. Shin. cited by applicant . U.S. Appl. No. 13/509,331, Sep. 16, 2013, T.A. Vivlemore. cited by applicant . U.S. Appl. No. 13/509,331, Jan. 28, 2013, T.A. Vivlemore. cited by applicant . U.S. Appl. No. 14/108,137, Apr. 29, 2015, T.A. Vivlemore. cited by applicant . U.S. Appl. No. 14/108,137, Oct. 3, 2014, T.A. Vivlemore. cited by applicant . U.S. Appl. No. 14/213,641, Mar. 31, 2015, D.H. Shin. cited by applicant . U.S. Appl. No. 14/213,641, Sep. 18, 2014, D.H. Shin. cited by applicant . U.S. Appl. No. 14/213,629, Aug. 21, 2015, E. Poliakova-Georgan. cited by applicant . U.S. Appl. No. 14/213,629, Dec. 29, 2014, E. Poliakova-Georgan. cited by applicant. |
Primary Examiner: Chong; Kimberly
Attorney, Agent or Firm:
